Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RC48”

81 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 81 results

Testing effectiveness (Phase 2)UnknownNCT05785325
What this trial is testing

RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 30
Large-scale testing (Phase 3)Looking for participantsNCT07693959
What this trial is testing

Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC

Who this might be right for
MIBC
Zhiquan Hu 170
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07279597
What this trial is testing

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Who this might be right for
Muscle-invasive Bladder Urothelial Carcinoma
Tongji Hospital 45
Testing effectiveness (Phase 2)UnknownNCT04965519
What this trial is testing

RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Who this might be right for
Gynecological Malignancy
RemeGen Co., Ltd. 120
Large-scale testing (Phase 3)Not Yet RecruitingNCT06944496
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 616
Early research (Phase 1)Study completedNCT02881138
What this trial is testing

RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Who this might be right for
Solid Tumors
RemeGen Co., Ltd. 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06385873
What this trial is testing

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Who this might be right for
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 32
Large-scale testing (Phase 3)Looking for participantsNCT05302284
What this trial is testing

RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaHER2-expressing
RemeGen Co., Ltd. 452
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Testing effectiveness (Phase 2)Study completedNCT03052634
What this trial is testing

RC48-ADC in Subjects With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RemeGen Co., Ltd. 112
Testing effectiveness (Phase 2)Looking for participantsNCT06001086
What this trial is testing

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Large-scale testing (Phase 3)Not Yet RecruitingNCT07366840
What this trial is testing

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Fudan University 268
Testing effectiveness (Phase 2)UnknownNCT06233864
What this trial is testing

The Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sun Yat-sen University 63
Testing effectiveness (Phase 2)UnknownNCT05313906
What this trial is testing

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

Who this might be right for
Advanced Gastric CarcinomaHER2-positive Gastric Cancer
Henan Cancer Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT05943379
What this trial is testing

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Who this might be right for
NMIBC
RemeGen Co., Ltd. 85
Testing effectiveness (Phase 2)UnknownNCT05601401
What this trial is testing

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Who this might be right for
Salivary Gland Tumors
Peking Union Medical College Hospital 10
Not applicableStudy completedNCT06168227
What this trial is testing

And Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 150
Testing effectiveness (Phase 2)Looking for participantsNCT05917158
What this trial is testing

RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

Who this might be right for
CarcinomaUpper Tract Urothelial CarcinomaUTUC
Jinling Hospital, China 30
Testing effectiveness (Phase 2)Study completedNCT04073602
What this trial is testing

RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
RemeGen Co., Ltd. 19
Next Page